FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews

Routine sharing of data between FDA and CMS will be possible for the first time under a June 23 memorandum of understanding that could serve as a first step toward parallel reviews for marketing approval and Medicare coverage